Verici Dx Plc

VRCI - LSE
Overview
Dividend safety
Dividends
Fundamentals
Add to watchlist

Add to calculator

Compare stock
Verici Dx Plc
VRCI
-
LSE
Overview
Dividend safety
Dividends
Fundamentals

Overview

Create a free account to get access to stock details and our dividend tracker

We won't send you any spam and we don't want a credit card.

About stock

Health care
Sector
Diagnostics & Research
Industry

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.

The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure.

Similar stocks

Based on sector and market capitalization

Report issue